Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05762705

A Mobile Gaming App to Improve Adherence to PrEP

In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthcare workers, clinic administrators, and patients taking PrEP) to inform intervention delivery. Data from the formative interviews will also be used to make necessary adaptations to the game and assess acceptability for diverse populations and clinics. Viral Combat will then be further tested with 200 participants ages 15-34 years, receiving PrEP care at clinical sites in the South (n=100 Jackson, MS) and New England (n=100, Providence, RI; Boston, MA) in a multisite Hybrid Type 1 effectiveness-implementation randomized controlled trial (RCT). This trial will test the efficacy of the intervention compared to a control condition (a non-PrEP related game) on biological and behavioral measures. At the end of the trial, a summative evaluation of the implementation context using the i-PARIHS framework will occur. These interviews with study participants and clinic staff will inform future implementation and dissemination of Viral Combat.

Recruiting

Interested in participating?

Request Info

Key information

About this study

In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthcare workers, clinic administrators, and patients taking PrEP) to inform intervention delivery. Data from the formative interviews will also be used to make necessary adaptations to the game and assess acceptability for diverse populations and clinics. Viral Combat will then be further tested with 200 participants ages 15-34 years, receiving PrEP care at clinical sites in the South (n=100 Jackson, MS) and New England (n=100, Providence, RI; Boston, MA) in a multisite Hybrid Type 1 effectiveness-implementation randomized controlled trial (RCT). This trial will test the efficacy of the intervention compared to a control condition (a non-PrEP related game) on biological and behavioral measures. At the end of the trial, a summative evaluation of the implementation context using the i-PARIHS framework will occur. These interviews with study participants and clinic staff will inform future implementation and dissemination of Viral Combat.

Aim 1: To conduct formative evaluation interviews, guided by the i-PARHIS framework, with approximately 30 stakeholders (23 PrEP patients, 4 clinical staff, 3 clinic administrators) in order to adapt Viral Combat for diverse PrEP patient populations, and to identify individual, organizational, and structural factors associated with its implementation.

Aim 2: To evaluate, in a Hybrid Type 1 effectiveness-implementation randomized controlled trial with 200 participants taking PrEP (15-34 years of age), the effectiveness of Viral Combat compared to a control group that receives a non-PrEP related game.

The investigators will examine the impact of the intervention on:

2a: improving adherence to PrEP using a biological measure (tenofovir from DBS), clinic records, and self-report; 2b: the potential mediators of the intervention, such as knowledge, motivation, self-efficacy, and game metrics.

Aim 3: To conduct summative evaluation interviews, following the RCT phase, with an additional 30 stakeholders ((23 PrEP patients, 4 clinical staff, 3 clinic administrators). Interviews will assess and summarize the i-PARIHS constructs relevant to the intervention's future implementation success.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 15-34 years old
  • English speaking
  • Initiated PrEP in the last 30 days or re-initiated PrEP after not taking PrEP for at least 1 month
  • HIV negative as per clinician and clinical record
  • Able to give consent/assent and not impaired by cognitive or medical limitations as per clinical assessment.

Exclusion criteria

  • None

Treatment and study plan

Multilevel Gaming Adherence Intervention

Behavioral

Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages

Treatment as Usual +

Behavioral

non-PrEP related mobile gaming application

Primary outcomes

  1. Tenofovir (TFV) blood concentration at 24 weeks

    Time frame: 24 weeks

    Tenofovir (TFV) concentration in blood from either venipuncture or dried blood spot labs immediately post-intervention (at 24 weeks follow-up).

Secondary outcomes

  1. Tenofovir (TFV) blood concentration at 48 weeks

    Time frame: 48 weeks

    Tenofovir (TFV) concentration in blood from either venipuncture or dried blood spot labs at the end of study follow-up (at 48 weeks follow-up).

  2. Self-reported Medication Adherence at 24 weeks

    Time frame: 24 weeks

    Proportion of days with missed doses via self-report: (reported missed doses in past month) / (total number of days in month) immediately post-intervention (at 24 weeks follow-up).

  3. Self-reported Medication Adherence at 48 weeks

    Time frame: 48 weeks

    Proportion of days with missed doses via self-report: (reported missed doses in past month) / (total number of days in month) at the end of study follow-up (at 48 weeks follow-up).

  4. Medical appointment adherence at 24 weeks

    Time frame: 24 weeks

    Number of PrEP-related medical visits kept in the past 3 months based on clinic records at 24 weeks follow-up.

  5. Medical appointment adherence at 48 weeks

    Time frame: 48 weeks

    Number of PrEP-related medical visits kept in the past 3 months based on clinic records at 48 weeks follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

James B Brock, MD

CONTACT

[email protected]

601-984-5560

Laura Whiteley, MD

CONTACT

[email protected]

(401)-455-6375

Sponsors and collaborators

Lead sponsor

Rhode Island Hospital

Other

Registry information

Official study title

A Multisite Randomized Trial of Viral Combat: A Mobile Gaming App to Improve Adherence to PrEP

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Mar 10, 2023
Registry last updated
May 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.